Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine

Comprehensive Psychiatry

Volumn 94, Issue , 2019, Pages

  Subramaniapillai, Mehala ^a   Mansur, Rodrigo B ^a,b   Zuckerman, Hannah ^a   Park, Caroline ^a,b   Lee, Yena ^a,b   Iacobucci, Michelle ^a   Cao, Bing ^a   Ho, R ^d   Lin, Kangguang ^e,f,g   Phan, Lee ^a   McIntyre, Roger S ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BRAIN AND COGNITION DISCOVERY FOUNDATION   (Canada)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e GUANGZHOU MEDICAL UNIVERSITY   (China)

^f JINAN UNIVERSITY   (China)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anhedonia; Major depressive disorder; MDD; Motivation; Reward; Vortioxetine

Indexed keywords

VORTIOXETINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COGNITION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DSM-5; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOTIVATION; OPEN STUDY; PATIENT DECISION MAKING; PROCESSING SPEED; TASK PERFORMANCE;

EID: 85070200660     PISSN: 0010440X     EISSN: 15328384     Source Type: Journal    
DOI: 10.1016/j.comppsych.2019.07.006     Document Type: Article

References (20)

1. Conradi, H.J., Ormel, J., de Jonge, P., Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 41 (2011), 1165–1174, 10.1017/S0033291710001911.
2. Fried, E.I., Nesse, R.M., The impact of individual depressive symptoms on impairment of psychosocial functioning. PLoS One 9 (2014), 1–7, 10.1371/journal.pone.0090311.
3. Goodwin, G.M., Price, J., De Bodinat, C., Laredo, J., Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord 221 (2017), 31–35, 10.1016/J.JAD.2017.05.048.
4. Gorwood, P., Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci 10 (2008), 291–299.
5. Botvinick, M., Braver, T., Motivation and cognitive control: from behavior to neural mechanism. Annu Rev Psychol 66 (2015), 83–113, 10.1146/annurev-psych-010814-015044.
6. Braver, T.S., Krug, M.K., Chiew, K.S., Kool, W., Westbrook, J.A., Clement, N.J., et al. Mechanisms of motivation—cognition interaction: challenges and opportunities. Cogn Affect Behav Neurosci 14 (2014), 443–472, 10.3758/s13415-014-0300-0.
7. Grahek, I., Shenhav, A., Musslick, S., Krebs, R.M., Koster, E.H.W., Motivation and cognitive control in depression. Neurosci Biobehav Rev 102 (2019), 371–381, 10.1016/J.NEUBIOREV.2019.04.011.
8. McIntyre, R.S., Woldeyohannes, H.O., Soczynska, J.K., Maruschak, N.A., Wium-Andersen, I.K., Vinberg, M., et al. Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project. CNS Spectr 21 (2016), 362–366, 10.1017/S1092852915000747.
9. Corruble, E., de Bodinat, C., Belaïdi, C., Goodwin, G.M., Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol 16 (2013), 2219–2234, 10.1017/S1461145713000679.
10. El Mansari, M., Guiard, B.P., Chernoloz, O., Ghanbari, R., Katz, N., Blier, P., Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther 16 (2010), e1–17, 10.1111/j.1755-5949.2010.00146.x.
11. Ghanbari, R., El Mansari, M., Blier, P., Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion. Psychopharmacology, 217, 2011, 61, 10.1007/s00213-011-2260-1.
12. Pehrson, A.L., Cremers, T., Bétry, C., van der Hart, M.G.C., Jørgensen, L., Madsen, M., et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol 23 (2013), 133–145, 10.1016/J.EURONEURO.2012.04.006.
13. Treadway, M.T., Buckholtz, J.W., Schwartzman, A.N., Lambert, W.E., Zald, D.H., Worth the “EEfRT”? The effort expenditure for rewards task as an objective measure of motivation and anhedonia. PLoS One, 4, 2009, e6598, 10.1371/journal.pone.0006598.
14. McIntyre, R., Harrison, J., Loft, H., Jacobson, W., Olsen, C., The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol, 19, 2016, pyw055, 10.1093/ijnp/pyw055.
15. Lee, Y., Rosenblat, J.D., Lee, J., Carmona, N.E., Subramaniapillai, M., Shekotikhina, M., et al. Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: a systematic review. J Affect Disord 227 (2018), 406–415, 10.1016/J.JAD.2017.11.003.
16. McIntyre, R., Best, M., Bowie, C., Carmona, N., Cha, D., Lee, Y., et al. The THINC-integrated tool (THINC-it) screening assessment for cognitive dysfunction: validation in patients with major depressive disorder. J Clin Psychiatry 78 (2017), 873–881, 10.4088/JCP.16M11329.
17. Cao, B., Park, C., Subramaniapillai, M., Lee, Y., Iacobucci, M., Mansur, R.B., et al. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder. Front. Psych., 10, 2019, 17, 10.3389/fpsyt.2019.00017.
18. Mørk, A., Montezinho, L.P., Miller, S., Trippodi-Murphy, C., Plath, N., Li, Y., et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav 105 (2013), 41–50, 10.1016/J.PBB.2013.01.019.
19. Pehrson, A.L., Sanchez, C., Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 19 (2014), 121–133, 10.1017/S1092852913000540.
20. Lu, Y., Ho, C.S., McIntyre, R.S., Wang, W., Ho, R.C., Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. Brain Res Bull 142 (2018), 1–7, 10.1016/J.BRAINRESBULL.2018.06.007.